cenerimod: Clinical Trials

3 trials of cenerimod, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 active not recruiting. 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Completed 2, Active not recruiting 1
Phase 11Completed 1

Follow cenerimod: new trials by email Literature Review of cenerimod trials Research Report on cenerimod

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)
cenerimod 4 mg - SLE - Systemic Lupus Erythematosus
Phase 2Active not recruitingViatris Pharmaceuticals Co., Ltd.152026-01-142026-07-28
Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Cenerimod 0.5 mg, Cenerimod 1 mg, Cenerimod 2 mg - Systemic Lupus Erythematosus
Phase 2CompletedViatris Innovation GmbH4272018-12-212026-07-29
Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus
Matching placebo, Cenerimod - Systemic Lupus Erythematosus
Phase 1 / Phase 2CompletedViatris Innovation GmbH1052015-06-012026-07-29

Conditions studied

Lupus Erythematosus, Systemic (3)  ·  Connective Tissue Diseases (1)

Sponsors

Viatris Innovation GmbH (2)  ·  Viatris Pharmaceuticals Co., Ltd. (1)

Countries

Bulgaria (2)  ·  Georgia (2)  ·  Russia (2)  ·  Ukraine (2)  ·  United States (2)  ·  Belarus (1)  ·  Chile (1)  ·  China (1)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)  ·  Greece (1)  ·  Hungary (1)  ·  Israel (1)  ·  Italy (1)

Results publications

PMID 31798918, PMID 39586304, PMID 39919901

NIH funding

2018 (1)